Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsviral clearance
Immunostimulants drugs38 0.56 [0.36; 0.89], 7 RCTs, I2=0% demonstrated
low degree of certainty
1.06 [0.78; 1.45], 5 RCTs, I2=45%
inconclusive result
1.05 [0.97; 1.13], 19 RCTs, I2=0%
inconclusive result
6.72 [2.07; 21.82], 2 RCTs, I2=0%
moderate degree of certainty
Immunosuppressants drugs33 0.79 [0.58; 1.08], 5 RCTs, I2=17%
inconclusive result
1.28 [1.11; 1.48], 10 RCTs, I2=37% demonstrated
low degree of certainty
0.86 [0.77; 0.97], 15 RCTs, I2=3% demonstrated
safety concern
inconclusive result
-
corticosteroids20 0.70 [0.40; 1.23], 5 RCTs, I2=73%
inconclusive result
3.34 [0.36; 30.90], 2 RCTs, I2=86%
inconclusive result
0.93 [0.83; 1.03], 12 RCTs, I2=37% demonstrated
inconclusive result
-
anti-inflammatory therapies5 OBS 0.43 [0.02; 8.34], 2 studies, I2=88%
inconclusive result
OBS 12.75 [1.61; 100.79], 1 study, I2=0%
unassessable degree of certainty
OBS 0.55 [0.29; 1.03], 2 studies, I2=15%
inconclusive result
-
acalabrutinib2----
leflunomide1 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result
- 1.00 [0.02; 52.54], 1 RCT, I2=0%
inconclusive result
-
A EFFACER anticorps0----
Apilimod0----
imatinib0----
pirfenidone0----
Polyinosinic-Polycytidylic Acid0----
sargramostim0----
thymosin0----